Drug intelligence / Profile preview

grazoprevir

Development stage: Phase 4
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

Grazoprevir is a second-generation, direct-acting antiviral drug used in combination therapy for the treatment of chronic hepatitis C virus (HCV) infection. It acts as an inhibitor of the HCV NS3/4A serine protease, an enzyme essential for viral replication and polyprotein processing. By inhibiting this protease, grazoprevir prevents the maturation of viral proteins necessary for HCV replication. Grazoprevir is effective against multiple HCV genotypes, including those resistant to other antivirals. It is administered orally and most commonly combined with elbasvir (an NS5A inhibitor) under the brand name Zepatier. The drug was developed by Merck and has completed Phase III trials.

Brand names: Zepatier

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)

Beyond the preview

Go deeper on grazoprevir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on grazoprevir.

Explore the full profile